antigen

vaccine dose

vaccination route

vaccination

rodent species

challenge doses

challenge virus

viremia/ total

survival/total

reference

ZEBOV-GP

2x 104 pfu

I.P

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

0/15

15/15

[22]

ZEBOV-GP

2x 104 pfu

I.P

day -28 & -14

BALB/c mice

1x 103 LD50

MA-ZEBOV

N.A

5/5

[22]

ZEBOV-GP

2x 104 pfu

I.P

day -28

BALB/c mice

1x 104 LD50

MA-ZEBOV

0/5

5/5

[22]

ZEBOV-GP

2x 104 pfu

I.P

day -28

BALB/c mice

1x 105 LD50

MA-ZEBOV

0/5

5/5

[22]

ZEBOV-GP

2x 104 pfu

I.P

day -28

BALB/c mice

1x 106 LD50

MA-ZEBOV

0/5

5/5

[22]

ZEBOV-GP

2x 103 pfu

I.P

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

N.A

5/5

[22]

ZEBOV-GP

2x 102 pfu

I.P

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

N.A

5/5

[22]

ZEBOV-GP

2x 101 pfu

I.P

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

N.A

5/5

[22]

ZEBOV-GP

2x 100 pfu

I.P

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

N.A

5/5

[22]

ZEBOV-GP

2x 104 pfu

I.M

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

0/5

5/5

[22]

ZEBOV-GP

2x 104 pfu

I.N

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

0/5

5/5

[22]

ZEBOV-GP

2x 104 pfu

ORAL

day -28

BALB/c mice

1x 103 LD50

MA-ZEBOV

0/10

10/10

[22]

ZEBOV-GP

2x 104 pfu

I.P

day -21

BALB/c mice

1x 103 LD50

MA-ZEBOV

0/20

20/20

[23]

ZEBOV-GP

2x 105 pfu

I.P

day -21

Guinea pig

1x 103 LD50

GPA-ZEBOV

N.A

14/14

[23]

ZEBOV-GP*

2x 105 pfu

I.P

day -21

Guinea pig

1x 103 LD50

GPA-ZEBOV

N.A

4/4

[23]

ZEBOV-GP

1x 105 pfu

I.P

day -28

Syrian hamster

1x 102 LD50

MA-ZEBOV

0/6

6/6

[24]

ZEBOV-GP

1x 105 pfu

I.P

day -14

Syrian hamster

1x 102 LD50

MA-ZEBOV

N.A

5/5

[24]

ZEBOV-GP

1x 105 pfu

I.P

day -7

Syrian hamster

1x 102 LD50

MA-ZEBOV

N.A

5/5

[24]

ZEBOV-GP

1x 105 pfu

I.P

day -3

Syrian hamster

1x 102 LD50

MA-ZEBOV

N.A

5/5

[24]
* ZEBOV-GP (strain Kikwit) N.D. = Not Determined
Table 1: Preventive EBOV rVSV vaccination studies in rodents.